Brokerages Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) Target Price at $33.00

Key Points

• Aardvark Therapeutics, Inc. has received an average recommendation of "Buy" from five research firms, with an average twelve-month target price of $33.00.
• Institutional investors have significantly increased their stakes in Aardvark Therapeutics, with Decheng Capital LLC leading by purchasing shares worth about $29.4 million.
• The company's stock opened at $13.47, showing a 12-month low of $4.88 and a high of $19.58, while it reported a loss of ($0.71) earnings per share in its most recent quarter.

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) has earned a consensus rating of "Buy" from the five research firms that are presently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $33.00.

Several research firms recently issued reports on AARD. Cantor Fitzgerald reissued an "overweight" rating and set a $50.00 price target on shares of Aardvark Therapeutics in a report on Tuesday, April 1st. HC Wainwright initiated coverage on shares of Aardvark Therapeutics in a report on Monday, June 30th. They issued a "buy" rating and a $40.00 target price for the company. Wall Street Zen cut shares of Aardvark Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Finally, Royal Bank Of Canada dropped their target price on shares of Aardvark Therapeutics from $21.00 to $20.00 and set an "outperform" rating for the company in a report on Thursday, May 15th.

Institutional Trading of Aardvark Therapeutics

Several large investors have recently modified their holdings of the business. Walleye Capital LLC acquired a new stake in shares of Aardvark Therapeutics in the first quarter valued at approximately $88,000. Goldman Sachs Group Inc. acquired a new stake in Aardvark Therapeutics during the first quarter worth approximately $153,000. Adage Capital Partners GP L.L.C. acquired a new stake in Aardvark Therapeutics during the first quarter worth approximately $1,878,000. Braidwell LP acquired a new stake in Aardvark Therapeutics during the first quarter worth approximately $3,755,000. Finally, Cormorant Asset Management LP acquired a new stake in Aardvark Therapeutics during the first quarter worth approximately $6,009,000.

Aardvark Therapeutics Stock Down 3.0%

NASDAQ AARD traded down $0.41 during trading hours on Friday, hitting $13.17. 8,399 shares of the stock were exchanged, compared to its average volume of 90,649. Aardvark Therapeutics has a 12-month low of $4.88 and a 12-month high of $19.58. The stock has a 50-day moving average of $12.23.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.01).

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.